Invitation to Stora Enso's Q2 2025 results webcast on 23 July 2025
HELSINKI, July 9, 2025 /PRNewswire/ -- Stora Enso will publish its Q2 results and Half-year Report for January–June 2025 on Wednesday 23 July at approximately 8:30 EEST (7:30 CEST).
Analysts, investors, and media are invited to participate in the webcast with a teleconference at 11:00 am EEST (10:00 CEST, 9:00 BST, 4:00 EDT) on the same day. The results will be presented by President and CEO Hans Sohlström and CFO Niclas Rosenlew. The presentation can be followed live via the link: https://stora-enso-oyj-q2-earnings-presentation-2025.open-exchange.net/
The webcast link will also be available on Stora Enso's website: storaenso.com/investors.
During the webcast presentation, analysts and investors will also have the possibility to ask questions. To participate in the teleconference, please choose the 'Teleconference' option on the homepage of the webcast.
A recording of the presentation will be available at https://stora-enso-oyj-q2-earnings-presentation-2025.open-exchange.net/ and on storaenso.com/en/investors/reports-and-presentations.
Media representatives who wish to ask questions after the publication of the Interim Report may contact Carl Norell, SVP Corporate Communications at Stora Enso on +46 72 241 0349.
Stora Enso
The forest is at the heart of Stora Enso, and we believe that everything made from fossil-based materials today can be made from a tree tomorrow. We are the leading provider of renewable products in packaging, biomaterials, and wooden construction, and one of the largest private forest owners in the world. Stora Enso has approximately 19,000 employees and our sales in 2024 were EUR 9 billion. Stora Enso shares are listed on Nasdaq Helsinki Oy (STEAV, STERV) and Nasdaq Stockholm AB (STE A, STE R). In addition, the shares are traded in the USA on OTC Markets (OTCQX) as ADRs and ordinary shares (SEOAY, SEOFF, SEOJF). storaenso.com/investors
STORA ENSO OYJ
Media enquiries:Carl NorellSVP Corporate Communicationstel. +46 72 241 0349Investor enquiries:Jutta MikkolaSVP Investor Relationstel. +358 50 544 6061
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/stora-enso-oyj/r/invitation-to-stora-enso-s-q2-2025-results-webcast-on-23-july-2025,c4204641
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-stora-ensos-q2-2025-results-webcast-on-23-july-2025-302501008.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Aviva enters into life insurance alliance with Tesco
Aviva has teamed up with Tesco Insurance & Money Services to introduce a life insurance product for Tesco's customers and Clubcard holders. The move aims to provide life cover while integrating Tesco's customer rewards programme into the offering. The life offering will be promoted through Tesco's online presence, social media channels and within hundreds of its UK stores, a press release from Aviva said. Customers can obtain a quote and apply for coverage via Tesco's insurance website. The insurance plan, underwritten by Aviva, starts at a monthly premium of £5 and is designed to be accessible through mobile devices. Aviva highlighted that its track record shows a high claim payout rate, with 98.8% of life insurance claims settled in 2024, totalling more than £862m ($1.16bn). Customers can also utilise additional complementary services for health and well-being. These services are offered at Aviva's discretion and may be subject to future changes or discontinuation. Tesco Insurance and Money Services Partnerships director Ban Mahsoub said: 'We are delighted to be working with Aviva to expand our offering into protection insurance for millions of Tesco customers and help meet the needs of families across the UK. 'Tesco's trusted brand backed by Aviva's expertise is bringing high-quality cover and real peace of mind for those who want to protect their loved ones.' Aviva Protection Distribution director Daren Boys stated: 'This new partnership is an exciting opportunity for our two brands to leverage our digital and data capabilities to bring life insurance to the forefront for Tesco customers across the UK. 'By combining Tesco's reach with Aviva's extensive expertise in protection, we are creating wider market awareness and greater access to insurance, to help more families feel financially resilient.' Last month, Aviva's Global, Corporate and Specialty division bolstered its Freight Liability insurance offering for the freight forwarding and haulage industries, with enhanced cover limits for both per tonne and per vehicle. "Aviva enters into life insurance alliance with Tesco " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 /PRNewswire/ -- ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 uses proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed element of a new CIRRUS software release, that also provides AI-enhanced OCTA image quality and multi-layer segmentation, helping to improve a practice's workflow efficiency and patient care. "At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience." "ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder." New research shows that physicians who leverage AI algorithms can be more effective than a practitioner alone. ZEISS CIRRUS with PathFinder delivers high-speed image capture with HD imaging detail 2, a wide field of view, and AI decision support, helping clinicians make more informed and efficient decisions. "With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support," says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. Improved clinical decision support – Without requiring export and data analysis from third-party platforms, CIRRUS PathFinder's fully integrated AI decision support algorithm interprets data within the clinician's current workflow, allowing for the assessment of many hundreds of scans at once, in real time, upleveling the value of a clinician's time. During image acquisition, this AI-guided workflow tool flags areas that may require more detailed imaging and, during review, allows the user to focus on what matters – improving patient care. Improved OCTA image quality – New CIRRUS operating software provides AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further enhances the user's diagnostic capability for even more efficient decision making. Enhanced connectivity and security – New cybersecurity features are designed to meet ever-evolving compliance and security needs. Additionally, the ZEISS CIRRUS platform ensures the seamless review of legacy OCT data combined with other diagnostic modalities to further enhance patient care. CIRRUS® PathFinder™ is available via license within the new CIRRUS software update, which includes an expanded Reference Database (RDB) that is triple the size of the previous RDB, cybersecurity enhancements, multi-layer segmentation, and improved OCTA visualization. The software update is available in select markets. For more information about CIRRUS PathFinder, go here. 1 ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.2 As it relates to the ZEISS CIRRUS 6000 only. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global CommunicationsZEISS OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: SOURCE Carl Zeiss Meditec AG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
European refiners may hold the key to scaling green hydrogen, says Wood Mackenzie
PRESS RELEASE European refiners may hold the key to scaling green hydrogen, says Wood Mackenzie • Globally, refining currently accounts for 36% of all hydrogen demand • EU regulations favor green over blue hydrogen • Strong policy is needed to reach targets and costs must come down • Marine and aviation sectors offer significant growth potential LONDON/HOUSTON/SINGAPORE, 21 August 2025 - High costs have kept green hydrogen projects from taking off, but new regulations in the European Union's (EU) refining sector offers a solution to launching this carbon friendly technology at scale, according to a new Horizons report from Wood Mackenzie. According to the report, 'Isn't it ironic? How Europe's oil refiners could offer a route to scale up green hydrogen', European refiners are set to require ~0.5 million tonnes of green hydrogen annually by 2030 to comply with EU regulations, replacing about 30% of current CO2-emitting hydrogen production. Refining represents one of the largest hydrogen opportunities globally, which, alongside ammonia and methanol production, accounts for 98% of current demand. The latest revision of the EU's Renewable Energy Directive (known as RED III), favors green hydrogen over blue hydrogen, helping to minimise the delays and cancellations now all too common when it comes to green hydrogen globally. "European refiners are set to become significant producers or buyers of green hydrogen, initially to decarbonise the refining sector and its derivatives as fuel for marine and aviation," said Alan Gelder. "Numerous green hydrogen projects have already targeted the sector." The report finds that of the 6 Mtpa of low-carbon hydrogen capacity that has taken a final investment decision (FID), European refineries have already committed more than US$5 billion of capital. Refiners demonstrate strongest market appetite Recent EU Hydrogen Bank auction results reveal refineries' commitment to green hydrogen adoption, with the sector showing the highest willingness to pay premium prices at an average levelised cost of hydrogen of US$9.23/kg - demonstrating their requirement to meet regulatory mandates. This compares favorably with Wood Mackenzie's asset-level modeling of refinery-targeted projects, which produces costs of US$7.04 to US$8.30/kg. The encouraging market signals extend beyond pricing. Average green hydrogen costs dropped 18% in the latest EU auctions, with German bids falling more than 55%. However, progress remains uneven across the bloc, with slow national adoption of RED III legislation hampering project development in many member states. Long-term growth lies in transport fuels While refinery decarbonization offers the strongest near-term investment case, the marine and aviation sectors present massive long-term growth opportunities for green hydrogen derivatives. The EU's ReFuelEU Aviation framework alone requires sustainable aviation fuel to power 6% of the jet pool by 2030, with 1.2% coming from green hydrogen-based e-fuels. By 2050, sustainable aviation fuel mandates could require 8 million tonnes of green hydrogen - representing a compound annual growth rate of over 15% for this sector alone. Similarly, Europe's FuelEU Maritime Regulation and the International Maritime Organization's Net Zero Framework are driving interest in hydrogen-derived marine fuels. "The opportunities for low-carbon hydrogen have come full circle," said Murray Douglas, Vice President of Hydrogen Research at Wood Mackenzie. "The traditional sectors of refining, ammonia and methanol are showing the most progress, ahead of the many other new demand sectors being touted for hydrogen. Parts of the refining sector can be decarbonised quickly – and at an acceptable cost. But it requires policy intervention to lower green hydrogen production costs and increase the refineries' offtake." Douglas added: "Marine and aviation hold much of the long-term potential for hydrogen derivatives, as these sectors are the most challenging to electrify. The challenge lies in competing fuels, the costs of production and the final shape of the policies providing support." Policy gaps remain key barrier Despite the progress, significant hurdles remain. Current EU policy requires RFNBOs to account for only 1% of transport sector energy use by 2030 - a modest target that reflects the challenges in expanding supply. Member states have been slow to transpose RED III into national legislation, creating regulatory uncertainty that has slowed project development across most of the EU. The report concludes that while European refiners could play a critical role in scaling up the green hydrogen industry, success depends on continued cost reductions and stronger policy support to fully kick-start demand across the continent. Read more here. ENDS For further information please contact Wood Mackenzie's media relations team: Mark Thomton+1 630 881 6885 Hla Myat Mon+65 8533 8860 Chris Boba+44 7408 Angelica The Big Partnership (UK PR agency)woodmac@ You have received this news release from Wood Mackenzie because of the details we hold about you. If the information we have is incorrect you can either provide your updated preferences by contacting our media relations team. If you do not wish to receive this type of email in the future, please reply with 'unsubscribe' in the subject header. About Wood Mackenzie Wood Mackenzie is the global insight business for renewables, energy and natural resources. Driven by data. Powered by people. In the middle of an energy revolution, businesses and governments need reliable and actionable insight to lead the transition to a sustainable future. That's why we cover the entire supply chain with unparalleled breadth and depth, backed by over 50 years' experience in natural resources. Today, our team of over 2,000 experts operate across 30 global locations, inspiring customers' decisions through real-time analytics, consultancy, events and thought leadership. Together, we deliver the insight they need to separate risk from opportunity and make bold decisions when it matters most. For more information, visit 登入存取你的投資組合 擷取數據時發生錯誤
